ZUMA-1 Five-Year Follow-Up Shows Axicabtagene Ciloleucel Treatment Success for Refractory Large B-Cell Lymphoma
John Theurer Cancer Center at Hackensack University Medical Center researchers assess outcomes for aggressive B-cell lymphoma treatment
A five-year follow-up of ZUMA-1 trial participants supports the curative potential of axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-Cell therapy in refractory large B-cell lymphoma. Researchers at John Theurer Cancer Center at Hackensack University Medical Center contributed to the study, with several notable findings:
- Five-year follow-up analysis demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL.
- Protracted B-cell aplasia was not required for durable responses.
- Axi-cel holds curative potential in a subset of patients with aggressive large B-cell lymphomas.
Investigator-assessed response, survival, safety and pharmacokinetics were analyzed in patients who received treatment in the ZUMA-1 trial. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up.
Learn more about innovations in cancer treatments at Hackensack University Medical Center.
